 |
 |
 |
 |
 |
 |
|
||||||
|
| EDITOR | |||
 |
Neil Love, MD Medical Oncologist Editor, Lung Cancer Update for Nurses Research To Practice Miami, Florida |
||
| FACULTY AFFILIATIONS | |||
 |
Ann Fish-Steagall, RN, BSN, OCN Clinical Coordinator Multidisciplinary Thoracic Oncology Program University of North Carolina at Chapel Hill Chapel Hill, North Carolina |
 |
Thomas J Lynch, MD Massachusetts General Hospital Chief, Hematology Oncology Director, Center for Thoracic Cancers Professor of Medicine Harvard Medical School Boston, Massachusetts |
 |
Mark A Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, North Carolina |
||
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Ms Fish-Steagall — Advisory Committee: Bristol-Myers Squibb Company, Genentech BioOncology; Consulting Agreement: Bristol-Myers Squibb Company; Speakers Bureau: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology. Dr Socinski — Paid Research: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, Pfizer Inc, Sanofi-Aventis; Speakers Bureau: Eli Lilly and Company, Genentech BioOncology, Sanofi-Aventis. Dr Lynch — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, ImClone Systems Incorporated, OSI Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi-Aventis; Patent for EGFR Testing: Genzyme Corporation.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
| Table of Contents | Top of Page |
